Time to first relapse.

Adverse events before and after initiation of treatment.

Remko Schats (661271)
Else M. Bijker (661270)
Geert-Jan van Gemert (250563)
Wouter Graumans (661274)
Marga van de Vegte-Bolmer (359384)
Lisette van Lieshout (179275)
Mariëlle C. Haks (3169299)
Cornelus C. Hermsen (113828)
Anja Scholzen (90403)
Leo G. Visser (193188)
Robert W. Sauerwein (82233)

May 2015

Average number of possibly and probably related (both solicited and unsolicited) AE per previousl...

A. Annualized relapse, rate (ARR) during the first year of fingolimod treatment compared to the year before fingolimod initiation. B. Correlation between ARR and the lymphocyte levels during the observation period. C. ARR during the first year of fingolimod treatment (black column) compared to the year before fingolimod initiation (white column) in treatment naïve and highly active treated patients.

Maria Rasenack (843780)
Jonathan Rychen (843781)
Michaela Andelova (513043)
Yvonne Naegelin (513042)
Christoph Stippich (513044)
Ludwig Kappos (253872)
Raija L. P. Lindberg (253855)
Till Sprenger (513046)
Tobias Derfuss (204827)

January 2016

A. Annualized relapse, rate (ARR) during the first year of fingolimod treatment compared to the y...

Rank Probability of Best Outcomes by Treatment for ARR.

Keith Tolley (572083)
Michael Hutchinson (133566)
Xiaojun You (748847)
Ping Wang (42415)
Bjoern Sperling (748848)
Ankush Taneja (748849)
Mohammed Kashif Siddiqui (748850)
Elizabeth Kinter (748851)

June 2015

Abbreviations: ARR, annualized relapse rate; CDP3M, 3-month confirmed disability progression; CDP...

Data of relapsed patients both at diagnosis and at relapse.

Mar García (293392)
Beatriz Bellosillo (223997)
Blanca Sánchez-González (293395)
Francesc García-Payarols (293397)
Agustin Seoane (293399)
Ana Maria Ferrer (293402)
Eva Gimeno (293404)
Luis Eugenio Barranco (293408)
Ariadna Torner (293412)
Francesc Solé (58588)
Carles Besses (293415)
Sergi Serrano (58587)
Antonio Salar (293419)

February 2013

HP: erradication therapy; F: Fludarabine; Chemo: Chemotherapy.*Time to relapse in months.<...

Primary clinical outcome over 2 years: non-inferiority of effect of AZA vs. IFN, represented as annualized relapse rate ratio (RRAZA/IFN) compared with the pre-established non-inferiority margin M ( = 1.23) and with a margin M1 = 1.0.

Luca Massacesi (662301)
Irene Tramacere (662302)
Salvatore Amoroso (174295)
Mario A. Battaglia (662303)
Maria Donata Benedetti (662304)
Graziella Filippini (662305)
Loredana La Mantia (662306)
Anna Repice (662307)
Alessandra Solari (397759)
Gioacchino Tedeschi (662308)
Clara Milanese (662309)

November 2014

One-sided 99% CI of the 0.67 ratio (upper-limit, UL = 1.12), represents an effect of A...

Predicted relapse rates for hypothetical regimens of 4, 6, and 8 months duration.

Robert S. Wallis (286546)
Thomas Peppard (731793)
David Hermann (731794)

April 2015

The prediction interval (PI) indicates uncertainty regarding the predicted relapse rate in a hypo...

Kaplan-Meier plot for cumulative incidence of remission.

Anne-Els van de Logt (825540)
Charles H. Beerenhout (825541)
Hans S. Brink (825542)
Jos J. van de Kerkhof (825543)
Jack F. Wetzels (825544)
Julia M. Hofstra (597618)

November 2015

Legend: Number of patients at risk for a remission at each time point are given below the figure....

Temporal pattern of relapses.

Ashish Narayan Masurekar (639465)
Catriona A. Parker (639466)
Milensu Shanyinde (639467)
Anthony V. Moorman (639468)
Jeremy P. Hancock (639469)
Rosemary Sutton (469966)
Philip J. Ancliff (639470)
Mary Morgan (639471)
Nicholas J. Goulden (639472)
Chris Fraser (639473)
Peter M. Hoogerbrugge (184736)
Tamas Revesz (639474)
Philip J. Darbyshire (639475)
Shekhar Krishnan (639476)
Sharon B. Love (639477)
Vaskar Saha (639478)

October 2014

Isolated (iCNS) and combined (c-CNS) relapses occur significantly earlier than those with isolate...

Exposure to treatment with interferon β-1a SC thrice weekly.

Tomas Kalincik (105432)
Timothy Spelman (317268)
Maria Trojano (301639)
Pierre Duquette (301652)
Guillermo Izquierdo (17842)
Pierre Grammond (301656)
Alessandra Lugaresi (317270)
Raymond Hupperts (235385)
Edgardo Cristiano (301666)
Vincent Van Pesch (301664)
Francois Grand’Maison (301649)
Daniele La Spitaleri (582612)
Maria Edite Rio (582613)
Sholmo Flechter (582614)
Celia Oreja-Guevara (301668)
Giorgio Giuliani (301660)
Aldo Savino (582615)
Maria Pia Amato (253050)
Thor Petersen (136208)
Ricardo Fernandez-Bolanos (317274)
Roberto Bergamaschi (25663)
Gerardo Iuliano (317272)
Cavit Boz (301662)
Jeannette Lechner-Scott (243997)
Norma Deri (582616)
Orla Gray (582617)
Freek Verheul (301670)
Marcela Fiol (301667)
Michael Barnett (317282)
Erik van Munster (341163)
Vetere Santiago (317281)
Fraser Moore (317277)
Mark Slee (301671)
Maria Laura Saladino (301669)
Raed Alroughani (582618)
Cameron Shaw (391365)
Krisztian Kasa (582619)
Tatjana Petkovska-Boskova (317275)
Leontien den Braber-Moerland (582620)
Joab Chapman (226918)
Eli Skromne (582621)
Joseph Herbert (312014)
Dieter Poehlau (582622)
Merrilee Needham (582623)
Elizabeth Alejandra Bacile Bacile (582624)
Walter Oleschko Arruda (582625)
Mark Paine (293593)
Bhim Singhal (582626)
Steve Vucic (391366)
Jose Antonio Cabrera-Gomez (317273)
Helmut Butzkueven (126230)

May 2013

Numbers of patients treated with Rebif recorded within the MSBase registry (n = 4678) and stratif...

Secondary clinical outcomes.

Luca Massacesi (662301)
Irene Tramacere (662302)
Salvatore Amoroso (174295)
Mario A. Battaglia (662303)
Maria Donata Benedetti (662304)
Graziella Filippini (662305)
Loredana La Mantia (662306)
Anna Repice (662307)
Alessandra Solari (397759)
Gioacchino Tedeschi (662308)
Clara Milanese (662309)

November 2014

Abbreviations: AZA, azathioprine; IFN, interferon.1P-values for AZA vs. IFN comparison wer...

Observed and predicted relapse rates in arms of three phase 3 trials of fluoroquinolone-containing regimens.

Robert S. Wallis (286546)
Thomas Peppard (731793)
David Hermann (731794)

April 2015

Evaluable subjects are those who at end-of-treatment have not met other unsatisfactory endpoints....

Kaplan-Meier plot for relapse free survival.

Anne-Els van de Logt (825540)
Charles H. Beerenhout (825541)
Hans S. Brink (825542)
Jos J. van de Kerkhof (825543)
Jack F. Wetzels (825544)
Julia M. Hofstra (597618)

November 2015

Legend: Number of patients at each time point are given below the figure. Log-rank test p = 0.020...

Number of events and incidence rates of clinical outcomes within 1 year for 2.5 mg BID apixaban and warfarin patients.

Xiaoyan Li (117291)
Allison Keshishian (2582335)
Melissa Hamilton (173102)
Ruslan Horblyuk (4801353)
Kiran Gupta (4042460)
Xuemei Luo (65327)
Jack Mardekian (88174)
Keith Friend (4801350)
Anagha Nadkarni (4801347)
Xianying Pan (4801356)
Gregory Y. H. Lip (195779)
Steve Deitelzweig (4801359)

January 2018

Number of events and incidence rates of clinical outcomes within 1 year for 2.5 mg BID apixaban a...

Time to relapse during the 100-week double-blind treatment with aripiprazole or placebo

D J Muzina (96157)
C Momah (96158)
J M Eudicone (96159)
A Pikalov (96160)
R D McQuade (96161)
R N Marcus (96162)
R Sanchez (96163)
B X Carlson (96164)

December 2011

Numbers of subjects remaining at each censoring time point are indicatedCopyright information:...

Flow-chart: patient allocation and follow-up.

Luca Massacesi (662301)
Irene Tramacere (662302)
Salvatore Amoroso (174295)
Mario A. Battaglia (662303)
Maria Donata Benedetti (662304)
Graziella Filippini (662305)
Loredana La Mantia (662306)
Anna Repice (662307)
Alessandra Solari (397759)
Gioacchino Tedeschi (662308)
Clara Milanese (662309)

November 2014

Abbreviations: AZA, azathioprine; IFN, interferon; ITT, intention to treat; PP, per-protocol. <su...

Adverse events before and after initiation of treatment.

Remko Schats (661271)
Else M. Bijker (661270)
Geert-Jan van Gemert (250563)
Wouter Graumans (661274)
Marga van de Vegte-Bolmer (359384)
Lisette van Lieshout (179275)
Mariëlle C. Haks (3169299)
Cornelus C. Hermsen (113828)
Anja Scholzen (90403)
Leo G. Visser (193188)
Robert W. Sauerwein (82233)

May 2015

Average number of possibly and probably related (both solicited and unsolicited) AE per previousl...

A. Annualized relapse, rate (ARR) during the first year of fingolimod treatment compared to the year before fingolimod initiation. B. Correlation between ARR and the lymphocyte levels during the observation period. C. ARR during the first year of fingolimod treatment (black column) compared to the year before fingolimod initiation (white column) in treatment naïve and highly active treated patients.

Maria Rasenack (843780)
Jonathan Rychen (843781)
Michaela Andelova (513043)
Yvonne Naegelin (513042)
Christoph Stippich (513044)
Ludwig Kappos (253872)
Raija L. P. Lindberg (253855)
Till Sprenger (513046)
Tobias Derfuss (204827)

January 2016

A. Annualized relapse, rate (ARR) during the first year of fingolimod treatment compared to the y...

Rank Probability of Best Outcomes by Treatment for ARR.

Keith Tolley (572083)
Michael Hutchinson (133566)
Xiaojun You (748847)
Ping Wang (42415)
Bjoern Sperling (748848)
Ankush Taneja (748849)
Mohammed Kashif Siddiqui (748850)
Elizabeth Kinter (748851)

June 2015

Abbreviations: ARR, annualized relapse rate; CDP3M, 3-month confirmed disability progression; CDP...

Data of relapsed patients both at diagnosis and at relapse.

Mar García (293392)
Beatriz Bellosillo (223997)
Blanca Sánchez-González (293395)
Francesc García-Payarols (293397)
Agustin Seoane (293399)
Ana Maria Ferrer (293402)
Eva Gimeno (293404)
Luis Eugenio Barranco (293408)
Ariadna Torner (293412)
Francesc Solé (58588)
Carles Besses (293415)
Sergi Serrano (58587)
Antonio Salar (293419)

February 2013

HP: erradication therapy; F: Fludarabine; Chemo: Chemotherapy.*Time to relapse in months.<...

Primary clinical outcome over 2 years: non-inferiority of effect of AZA vs. IFN, represented as annualized relapse rate ratio (RRAZA/IFN) compared with the pre-established non-inferiority margin M ( = 1.23) and with a margin M1 = 1.0.

Luca Massacesi (662301)
Irene Tramacere (662302)
Salvatore Amoroso (174295)
Mario A. Battaglia (662303)
Maria Donata Benedetti (662304)
Graziella Filippini (662305)
Loredana La Mantia (662306)
Anna Repice (662307)
Alessandra Solari (397759)
Gioacchino Tedeschi (662308)
Clara Milanese (662309)

November 2014

One-sided 99% CI of the 0.67 ratio (upper-limit, UL = 1.12), represents an effect of A...

Predicted relapse rates for hypothetical regimens of 4, 6, and 8 months duration.

Robert S. Wallis (286546)
Thomas Peppard (731793)
David Hermann (731794)

April 2015

The prediction interval (PI) indicates uncertainty regarding the predicted relapse rate in a hypo...

Kaplan-Meier plot for cumulative incidence of remission.

Anne-Els van de Logt (825540)
Charles H. Beerenhout (825541)
Hans S. Brink (825542)
Jos J. van de Kerkhof (825543)
Jack F. Wetzels (825544)
Julia M. Hofstra (597618)

November 2015

Legend: Number of patients at risk for a remission at each time point are given below the figure....

Temporal pattern of relapses.

Ashish Narayan Masurekar (639465)
Catriona A. Parker (639466)
Milensu Shanyinde (639467)
Anthony V. Moorman (639468)
Jeremy P. Hancock (639469)
Rosemary Sutton (469966)
Philip J. Ancliff (639470)
Mary Morgan (639471)
Nicholas J. Goulden (639472)
Chris Fraser (639473)
Peter M. Hoogerbrugge (184736)
Tamas Revesz (639474)
Philip J. Darbyshire (639475)
Shekhar Krishnan (639476)
Sharon B. Love (639477)
Vaskar Saha (639478)

October 2014

Isolated (iCNS) and combined (c-CNS) relapses occur significantly earlier than those with isolate...

Exposure to treatment with interferon β-1a SC thrice weekly.

Tomas Kalincik (105432)
Timothy Spelman (317268)
Maria Trojano (301639)
Pierre Duquette (301652)
Guillermo Izquierdo (17842)
Pierre Grammond (301656)
Alessandra Lugaresi (317270)
Raymond Hupperts (235385)
Edgardo Cristiano (301666)
Vincent Van Pesch (301664)
Francois Grand’Maison (301649)
Daniele La Spitaleri (582612)
Maria Edite Rio (582613)
Sholmo Flechter (582614)
Celia Oreja-Guevara (301668)
Giorgio Giuliani (301660)
Aldo Savino (582615)
Maria Pia Amato (253050)
Thor Petersen (136208)
Ricardo Fernandez-Bolanos (317274)
Roberto Bergamaschi (25663)
Gerardo Iuliano (317272)
Cavit Boz (301662)
Jeannette Lechner-Scott (243997)
Norma Deri (582616)
Orla Gray (582617)
Freek Verheul (301670)
Marcela Fiol (301667)
Michael Barnett (317282)
Erik van Munster (341163)
Vetere Santiago (317281)
Fraser Moore (317277)
Mark Slee (301671)
Maria Laura Saladino (301669)
Raed Alroughani (582618)
Cameron Shaw (391365)
Krisztian Kasa (582619)
Tatjana Petkovska-Boskova (317275)
Leontien den Braber-Moerland (582620)
Joab Chapman (226918)
Eli Skromne (582621)
Joseph Herbert (312014)
Dieter Poehlau (582622)
Merrilee Needham (582623)
Elizabeth Alejandra Bacile Bacile (582624)
Walter Oleschko Arruda (582625)
Mark Paine (293593)
Bhim Singhal (582626)
Steve Vucic (391366)
Jose Antonio Cabrera-Gomez (317273)
Helmut Butzkueven (126230)

May 2013

Numbers of patients treated with Rebif recorded within the MSBase registry (n = 4678) and stratif...

Secondary clinical outcomes.

Luca Massacesi (662301)
Irene Tramacere (662302)
Salvatore Amoroso (174295)
Mario A. Battaglia (662303)
Maria Donata Benedetti (662304)
Graziella Filippini (662305)
Loredana La Mantia (662306)
Anna Repice (662307)
Alessandra Solari (397759)
Gioacchino Tedeschi (662308)
Clara Milanese (662309)

November 2014

Abbreviations: AZA, azathioprine; IFN, interferon.1P-values for AZA vs. IFN comparison wer...

Observed and predicted relapse rates in arms of three phase 3 trials of fluoroquinolone-containing regimens.

Robert S. Wallis (286546)
Thomas Peppard (731793)
David Hermann (731794)

April 2015

Evaluable subjects are those who at end-of-treatment have not met other unsatisfactory endpoints....

Kaplan-Meier plot for relapse free survival.

Anne-Els van de Logt (825540)
Charles H. Beerenhout (825541)
Hans S. Brink (825542)
Jos J. van de Kerkhof (825543)
Jack F. Wetzels (825544)
Julia M. Hofstra (597618)

November 2015

Legend: Number of patients at each time point are given below the figure. Log-rank test p = 0.020...

Number of events and incidence rates of clinical outcomes within 1 year for 2.5 mg BID apixaban and warfarin patients.

Xiaoyan Li (117291)
Allison Keshishian (2582335)
Melissa Hamilton (173102)
Ruslan Horblyuk (4801353)
Kiran Gupta (4042460)
Xuemei Luo (65327)
Jack Mardekian (88174)
Keith Friend (4801350)
Anagha Nadkarni (4801347)
Xianying Pan (4801356)
Gregory Y. H. Lip (195779)
Steve Deitelzweig (4801359)

January 2018

Number of events and incidence rates of clinical outcomes within 1 year for 2.5 mg BID apixaban a...

Time to relapse during the 100-week double-blind treatment with aripiprazole or placebo

D J Muzina (96157)
C Momah (96158)
J M Eudicone (96159)
A Pikalov (96160)
R D McQuade (96161)
R N Marcus (96162)
R Sanchez (96163)
B X Carlson (96164)

December 2011

Numbers of subjects remaining at each censoring time point are indicatedCopyright information:...

Flow-chart: patient allocation and follow-up.

Luca Massacesi (662301)
Irene Tramacere (662302)
Salvatore Amoroso (174295)
Mario A. Battaglia (662303)
Maria Donata Benedetti (662304)
Graziella Filippini (662305)
Loredana La Mantia (662306)
Anna Repice (662307)
Alessandra Solari (397759)
Gioacchino Tedeschi (662308)
Clara Milanese (662309)

November 2014

Abbreviations: AZA, azathioprine; IFN, interferon; ITT, intention to treat; PP, per-protocol. <su...

Adverse events before and after initiation of treatment.

Remko Schats (661271)
Else M. Bijker (661270)
Geert-Jan van Gemert (250563)
Wouter Graumans (661274)
Marga van de Vegte-Bolmer (359384)
Lisette van Lieshout (179275)
Mariëlle C. Haks (3169299)
Cornelus C. Hermsen (113828)
Anja Scholzen (90403)
Leo G. Visser (193188)
Robert W. Sauerwein (82233)

May 2015

Average number of possibly and probably related (both solicited and unsolicited) AE per previousl...

A. Annualized relapse, rate (ARR) during the first year of fingolimod treatment compared to the year before fingolimod initiation. B. Correlation between ARR and the lymphocyte levels during the observation period. C. ARR during the first year of fingolimod treatment (black column) compared to the year before fingolimod initiation (white column) in treatment naïve and highly active treated patients.

Maria Rasenack (843780)
Jonathan Rychen (843781)
Michaela Andelova (513043)
Yvonne Naegelin (513042)
Christoph Stippich (513044)
Ludwig Kappos (253872)
Raija L. P. Lindberg (253855)
Till Sprenger (513046)
Tobias Derfuss (204827)

January 2016

A. Annualized relapse, rate (ARR) during the first year of fingolimod treatment compared to the y...

Rank Probability of Best Outcomes by Treatment for ARR.

Keith Tolley (572083)
Michael Hutchinson (133566)
Xiaojun You (748847)
Ping Wang (42415)
Bjoern Sperling (748848)
Ankush Taneja (748849)
Mohammed Kashif Siddiqui (748850)
Elizabeth Kinter (748851)

June 2015

Abbreviations: ARR, annualized relapse rate; CDP3M, 3-month confirmed disability progression; CDP...

Time to first relapse.

Abstract

Extracted data

Time to first relapse.

Abstract

Extracted data

Related items

Related items